CytomX Therapeutics Inc (CTMX) — Cash Flow Quality Index

Latest as of March 2025: -0.89x

CytomX Therapeutics Inc (CTMX) has a Cash Flow Quality Index of -0.89x as of March 2025. Operating cash flow of $-21.04 Million is below net income of $23.52 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore CTMX cash flow metrics to assess how effectively this company generates cash.

Cash Flow Quality Index

-0.89x
Operating CF / Net Income

Operating Cash Flow

$-21.04 Million
USD

Net Income

$23.52 Million
USD

Data as of

Mar 2025
Most recent filing

CytomX Therapeutics Inc Cash Flow Quality Index (2024–2024)

Historical Cash Flow Quality Index for CytomX Therapeutics Inc across 1 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check CytomX Therapeutics Inc total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.

Annual Cash Flow Quality Index for CytomX Therapeutics Inc (2024–2024)

Year-by-year earnings quality comparison for CytomX Therapeutics Inc. For live market cap and the full company financial profile, see CTMX market cap.

Year Quality Index Operating CF (USD) Net Income YoY Change
2024 -2.71x $-86.23 Million $31.87 Million
Cash Flow Quality Index = Operating Cash Flow / Net Income. Ratios above 1.0x indicate cash-backed earnings.